Rafferty Asset Management
FOLD

Rafferty Asset Management’s Amicus Therapeutics FOLD Stock Holding History

Rafferty Asset Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.54M Sell
313,882
-179,206
-36% -$2.57M 0.02% 419
2025
Q4 		$7.02M Buy
493,088
+114,359
+30% +$1.12M 0.02% 332
2025
Q3 		$2.98M Sell
378,729
-36,309
-9% -$258K 0.01% 550
2025
Q2 		$2.38M Buy
415,038
+161,274
+64% +$1.04M 0.01% 561
2025
Q1 		$2.07M Sell
253,764
-79,627
-24% -$737K 0.01% 570
2024
Q4 		$3.14M Sell
333,391
-73,883
-18% -$768K 0.01% 514
2024
Q3 		$4.35M Sell
407,274
-49,395
-11% -$538K 0.01% 454
2024
Q2 		$4.53M Sell
456,669
-288,905
-39% -$2.97M 0.02% 441
2024
Q1 		$8.78M Sell
745,574
-49,777
-6% -$637K 0.03% 317
2023
Q4 		$11.3M Buy
795,351
+87,112
+12% +$989K 0.05% 238
2023
Q3 		$8.61M Buy
708,239
+59,727
+9% +$770K 0.05% 261
2023
Q2 		$8.15M Buy
648,512
+53,811
+9% +$639K 0.05% 266
2023
Q1 		$6.6M Sell
594,701
-95,068
-14% -$1.17M 0.04% 312
2022
Q4 		$8.42M Buy
689,769
+83,009
+14% +$934K 0.07% 239
2022
Q3 		$6.33M Buy
606,760
+136,451
+29% +$1.52M 0.07% 271
2022
Q2 		$5.05M Sell
470,309
-118,275
-20% -$974K 0.05% 275
2022
Q1 		$5.57M Buy
588,584
+63,739
+12% +$598K 0.03% 363
2021
Q4 		$6.06M Buy
524,845
+220,295
+72% +$2.46M 0.03% 298
2021
Q3 		$2.91M Buy
304,550
+58,924
+24% +$603K 0.02% 494
2021
Q2 		$2.37M Sell
245,626
-63,446
-21% -$619K 0.01% 634
2021
Q1 		$3.05M Buy
309,072
+266,892
+633% +$4.13M 0.02% 484
2020
Q4 		$974K Sell
42,180
-111,751
-73% -$2.29M 0.01% 502
2020
Q3 		$2.17M Buy
153,931
+66,546
+76% +$970K 0.03% 394
2020
Q2 		$1.32M Buy
87,385
+51,694
+145% +$630K 0.02% 468
2020
Q1 		$330K Sell
35,691
-267,635
-88% -$2.54M 0.01% 414
2019
Q4 		$2.95M Sell
303,326
-345,646
-53% -$3.16M 0.05% 223
2019
Q3 		$5.21M Buy
648,972
+213,367
+49% +$2.32M 0.08% 149
2019
Q2 		$5.44M Buy
435,605
+79,212
+22% +$1.01M 0.1% 144
2019
Q1 		$4.85M Buy
+356,393
New +$4.35M 0.08% 144

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Rafferty Asset Management's FOLD Position: Q1 2026 in Review

Rafferty Asset Management reduced its Amicus Therapeutics (FOLD) stake by 36% in Q1 2026, selling an estimated $2.57M and leaving 313,882 shares worth $4.54M. The position accounts for 0.02% of the portfolio, ranked #419.

Rafferty Asset Management first reported a position in FOLD in Q1 2019 and has held it in 29 quarters since. The position peaked at $11.3M in Q4 2023. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Rafferty Asset Management held 313,882 shares of Amicus Therapeutics worth $4.54M as of Q1 2026.
  • Rafferty Asset Management sold 179,206 Amicus Therapeutics shares in Q1 2026, an estimated $2.57M.
  • Amicus Therapeutics made up 0.02% of Rafferty Asset Management's portfolio in Q1 2026, its #419 holding.
  • Rafferty Asset Management first reported a position in Amicus Therapeutics in Q1 2019 and has held it in 29 quarters since.
  • Rafferty Asset Management's Amicus Therapeutics position peaked at $11.3M in Q4 2023.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Rafferty Asset Management's 13F filing for Q1 2026, filed 15 May 2026.